Geoffrey Beran Rose Sells 7,879 Shares of Pulmonx (NASDAQ:LUNG) Stock

Pulmonx Corporation (NASDAQ:LUNG) insider Geoffrey Rose sold 7,879 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $2.26, for a total transaction of $17,806.54. Following the sale, the insider owned 449,832 shares in the company, valued at $1,016,620.32. This represents a 1.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Pulmonx Stock Performance

Shares of NASDAQ:LUNG opened at $2.21 on Friday. Pulmonx Corporation has a 1 year low of $1.13 and a 1 year high of $2.89. The stock has a market capitalization of $94.92 million, a price-to-earnings ratio of -1.91 and a beta of 0.34. The company has a debt-to-equity ratio of 0.95, a current ratio of 4.32 and a quick ratio of 3.52. The company’s 50 day simple moving average is $1.82 and its 200 day simple moving average is $1.57.

Pulmonx (NASDAQ:LUNG) last released its earnings results on Wednesday, July 29th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.04. Pulmonx had a negative return on equity of 96.66% and a negative net margin of 55.03%.The firm had revenue of $22.76 million during the quarter, compared to analysts’ expectations of $22.39 million. As a group, research analysts predict that Pulmonx Corporation will post -1.05 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on LUNG. Weiss Ratings raised shares of Pulmonx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 25th. Wall Street Zen raised shares of Pulmonx from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Pulmonx presently has a consensus rating of “Moderate Buy” and an average target price of $7.67.

Pulmonx News Summary

Here are the key news stories impacting Pulmonx this week:

• Positive Sentiment: Analyst sentiment remains broadly favorable, with three Buy ratings and one Sell rating producing a “Moderate Buy” consensus. The average price target of $7.67 is substantially above recent trading levels, suggesting significant potential upside if Pulmonx delivers on its growth plans. Pulmonx analyst and earnings information
• Positive Sentiment: Pulmonx’s latest quarterly results exceeded expectations: revenue was $22.76 million versus the $22.39 million consensus estimate, while its loss of $0.24 per share was narrower than the expected $0.28 loss. Pulmonx quarterly results
• Neutral Sentiment: CEO Glendon French III, General Counsel David Lehman, Geoffrey Rose and Srikanth Radhakrishnan sold a combined 78,340 shares at approximately $2.26 per share. The filings say the transactions covered tax-withholding obligations related to vested equity awards, reducing their significance as a signal of declining confidence; however, the sales may add modest short-term supply. Pulmonx insider sales report
• Negative Sentiment: Recent gains have triggered profit-taking, contributing to the stock’s retreat and weakening short-term trading sentiment. Pulmonx shares fall following recent gains
• Negative Sentiment: Pulmonx remains unprofitable, and analysts expect a full-year loss of roughly $1.05 per share. The company’s negative margins and uncertain path to sustained profitability are keeping investors cautious despite the earnings beat. Pulmonx profit-taking and earnings outlook

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Stonepine Capital Management LLC acquired a new stake in Pulmonx during the 2nd quarter worth approximately $1,060,067. ADAR1 Capital Management LLC acquired a new position in Pulmonx in the 2nd quarter valued at approximately $526,000. Parkman Healthcare Partners LLC acquired a new position in Pulmonx in the 2nd quarter valued at approximately $841,000. Deutsche Bank AG bought a new position in shares of Pulmonx during the second quarter valued at $523,000. Finally, Primecap Management Co. CA bought a new position in shares of Pulmonx during the second quarter valued at $5,996,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.